Immuneering (NASDAQ:IMRX) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Immuneering (NASDAQ:IMRX) in a report published on Monday,Benzinga reports. They currently have a $11.00 target price on the stock.

IMRX has been the topic of several other reports. Wall Street Zen upgraded Immuneering from a “sell” rating to a “hold” rating in a report on Saturday. Chardan Capital reiterated a “buy” rating and set a $20.00 target price on shares of Immuneering in a research note on Thursday, November 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Immuneering Price Performance

Shares of IMRX stock opened at $5.62 on Monday. The company’s fifty day moving average price is $5.20 and its two-hundred day moving average price is $6.13. The firm has a market capitalization of $362.88 million, a P/E ratio of -4.07 and a beta of 0.46. Immuneering has a 12 month low of $1.10 and a 12 month high of $10.08.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Friday, March 6th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.13. On average, sell-side analysts anticipate that Immuneering will post -1.86 EPS for the current year.

Insider Transactions at Immuneering

In other Immuneering news, Director Peter Feinberg purchased 20,000 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was acquired at an average cost of $4.35 per share, with a total value of $87,000.00. Following the acquisition, the director owned 135,441 shares of the company’s stock, valued at approximately $589,168.35. This represents a 17.32% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Thomas J. Schall acquired 21,645 shares of the stock in a transaction that occurred on Thursday, January 15th. The shares were acquired at an average cost of $4.67 per share, with a total value of $101,082.15. Following the transaction, the director owned 74,530 shares in the company, valued at approximately $348,055.10. The trade was a 40.93% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders bought 51,819 shares of company stock worth $234,472. Insiders own 22.90% of the company’s stock.

Hedge Funds Weigh In On Immuneering

Several institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Immuneering during the 4th quarter worth approximately $33,000. China Universal Asset Management Co. Ltd. acquired a new position in Immuneering during the 3rd quarter valued at approximately $35,000. Future Financial Wealth Managment LLC acquired a new position in Immuneering during the 3rd quarter valued at approximately $35,000. Mercer Global Advisors Inc. ADV bought a new position in Immuneering during the 3rd quarter worth $70,000. Finally, SummitTX Capital L.P. acquired a new stake in Immuneering in the fourth quarter worth $69,000. 67.65% of the stock is owned by institutional investors.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.